Repligen | RGEN - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Agilent USD 475M 10M 2026-06
Align Technology USD 410.55M 52.12M 2026-09
Bio Techne USD 67.42M 41.91M 2026-06
BioMarin Pharmaceutical USD 333.64M 61.91M 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Bruker USD 226.5M 12.4M 2026-09
Charles River Laboratories USD 140.59M 88.31M 2026-09
Danaher USD 2.16B 87M 2026-09
Dentsply International USD 363M 1000K 2026-09
General Electric Aerospace USD 1.09B 40M 2026-09
Henry Schein USD 819M 12M 2026-09
Illumina USD 281M 8M 2026-09
IQVIA Holdings USD 569M 5M 2026-09
Mettler Toledo International USD 267.16M 3.82M 2026-09
Myriad Genetics USD 122.3M 6.7M 2025-12
OraSure Technologies USD 13.21M 3.29M 2025-12
Pacific Biosciences Of California USD 37.24M 25.68M 2025-12
Pfizer USD 3.28B 132M 2026-09
Repligen USD 83.59M 6.97M 2026-09
Revvity USD 275.33M 3.25M 2026-09
Standard Biotools USD 16.39M 2.22M 2026-06
Thermo Fisher Scientific USD 1.86B 46M 2026-09
Waters USD 398M 7M 2026-09
West Pharmaceutical Services USD 112.9M 4.7M 2026-09